Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 6 December 2024, including: Zepbound bests Wegovy; Novartis and PTC’s Huntingdon’s deal; Vabysmo hopes to ride new listing, data in Asia; Leo Pharma gains momentum; and Immunic’s hopes for MS drug.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
Lilly’s Head-To-Head Trial Reaffirms Zepbound Efficacy Versus Wegovy
PTC Gets $1bn From Novartis For Phase II Huntington’s Candidate
Vabysmo Hopes To Ride New Coverage In China, Data To Expand In Asia
Leo Pharma Picks Up Momentum As Growth Plan Progresses
Broad Benefits Of Immunic MS Drug Could Transform Treatment
